[Breast cancer with axillary lymph node involvement]. 2010

A Belaid, and S Kanoun, and A Kallel, and I Ghorbel, and F Azoury, and S Heymann, and C Pichenot, and R Verstraet, and H Marsiglia, and C Bourgier
Département de radiothérapie, Unité fonctionnelle de Sénologie, institut Gustave-Roussy, Villejuif, France.

Breast cancer is the most frequent cancer of women in western countries. There are one million new cases per year in the world which represents 22% of all female cancers, and more than 370,000 deaths due to breast cancer per year (14% of cancer mortality). More than half of breast cancers are associated with axillary nodal involvement. Post-operative radiation therapy (XRT) is a crucial part of locoregional treatment in axillary nodal involvement breast cancer owing to a 15-years risk reduction of locoregional recurrence of 70% and to a 5.4% risk reduction of specific mortality. In 3D-conformal irradiation in such breast cancers, target volumes are chest wall when mastectomy was performed or breast and boost of tumor bed in case of breast conservative surgery, and supra-clavicular and/or axillary and/or internal mammary node areas. The main organs at risk are ipsilateral lung, heart and brachial plexus. The aim of this article is to describe epidemiologic, radio anatomic and prognostic features of axillary nodal involvement breast cancer and to propose guidelines for 3D-conformal treatment planning in locally advanced breast cancers. This review is illustrated by a case report.

UI MeSH Term Description Entries
D008198 Lymph Nodes They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system. Lymph Node,Node, Lymph,Nodes, Lymph
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D008408 Mastectomy Surgical procedure to remove one or both breasts. Mammectomy,Mammectomies,Mastectomies
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015994 Incidence The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases in the population at a given time. Attack Rate,Cumulative Incidence,Incidence Proportion,Incidence Rate,Person-time Rate,Secondary Attack Rate,Attack Rate, Secondary,Attack Rates,Cumulative Incidences,Incidence Proportions,Incidence Rates,Incidence, Cumulative,Incidences,Person time Rate,Person-time Rates,Proportion, Incidence,Rate, Attack,Rate, Incidence,Rate, Person-time,Rate, Secondary Attack,Secondary Attack Rates
D015996 Survival Rate The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods. Cumulative Survival Rate,Mean Survival Time,Cumulative Survival Rates,Mean Survival Times,Rate, Cumulative Survival,Rate, Survival,Rates, Cumulative Survival,Rates, Survival,Survival Rate, Cumulative,Survival Rates,Survival Rates, Cumulative,Survival Time, Mean,Survival Times, Mean,Time, Mean Survival,Times, Mean Survival
D020266 Radiotherapy, Conformal A therapy using IONIZING RADIATION where there is improved dose homogeneity within the tumor and reduced dosage to uninvolved structures. The precise shaping of dose distribution is achieved via the use of computer-controlled multileaf collimators. Conformal Radiotherapy,3-D Conformal Radiotherapy,Three-Dimensional Conformal Radiotherapy,3-D Conformal Radiotherapies,Conformal Radiotherapies,Conformal Radiotherapies, 3-D,Conformal Radiotherapies, Three-Dimensional,Conformal Radiotherapy, 3-D,Conformal Radiotherapy, Three-Dimensional,Radiotherapies, 3-D Conformal,Radiotherapies, Conformal,Radiotherapies, Three-Dimensional Conformal,Radiotherapy, 3-D Conformal,Radiotherapy, Three-Dimensional Conformal,Three Dimensional Conformal Radiotherapy,Three-Dimensional Conformal Radiotherapies

Related Publications

A Belaid, and S Kanoun, and A Kallel, and I Ghorbel, and F Azoury, and S Heymann, and C Pichenot, and R Verstraet, and H Marsiglia, and C Bourgier
January 2011, The breast journal,
A Belaid, and S Kanoun, and A Kallel, and I Ghorbel, and F Azoury, and S Heymann, and C Pichenot, and R Verstraet, and H Marsiglia, and C Bourgier
January 2001, Breast cancer (Tokyo, Japan),
A Belaid, and S Kanoun, and A Kallel, and I Ghorbel, and F Azoury, and S Heymann, and C Pichenot, and R Verstraet, and H Marsiglia, and C Bourgier
July 1999, Journal of surgical oncology,
A Belaid, and S Kanoun, and A Kallel, and I Ghorbel, and F Azoury, and S Heymann, and C Pichenot, and R Verstraet, and H Marsiglia, and C Bourgier
October 2022, Annals of surgical oncology,
A Belaid, and S Kanoun, and A Kallel, and I Ghorbel, and F Azoury, and S Heymann, and C Pichenot, and R Verstraet, and H Marsiglia, and C Bourgier
April 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology,
A Belaid, and S Kanoun, and A Kallel, and I Ghorbel, and F Azoury, and S Heymann, and C Pichenot, and R Verstraet, and H Marsiglia, and C Bourgier
June 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
A Belaid, and S Kanoun, and A Kallel, and I Ghorbel, and F Azoury, and S Heymann, and C Pichenot, and R Verstraet, and H Marsiglia, and C Bourgier
December 2013, Balkan medical journal,
A Belaid, and S Kanoun, and A Kallel, and I Ghorbel, and F Azoury, and S Heymann, and C Pichenot, and R Verstraet, and H Marsiglia, and C Bourgier
November 1999, The Medical journal of Australia,
A Belaid, and S Kanoun, and A Kallel, and I Ghorbel, and F Azoury, and S Heymann, and C Pichenot, and R Verstraet, and H Marsiglia, and C Bourgier
June 2004, Medicina clinica,
A Belaid, and S Kanoun, and A Kallel, and I Ghorbel, and F Azoury, and S Heymann, and C Pichenot, and R Verstraet, and H Marsiglia, and C Bourgier
January 2000, Breast cancer (Tokyo, Japan),
Copied contents to your clipboard!